SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (28)
2024
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
2023
-
Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab
JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846
-
Impact of the COVID-19 Lockdown on Physical Activity Levels and Health Parameters in Young Adults with Cancer
Current Oncology, Vol. 30, Núm. 6, pp. 5395-5408
2022
-
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Cancers, Vol. 14, Núm. 3
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
2020
-
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724
2019
2018
-
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829
-
Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification
Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852
2017
-
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts
Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657
-
Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial (Breast Cancer Research and Treatment, (2016), 156, 3, (507-515), 10.1007/s10549-016-3792-1)
Breast Cancer Research and Treatment
-
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189
2016
-
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
Breast Cancer Research and Treatment, Vol. 156, Núm. 3, pp. 507-515
-
Review: circulating tumor cells in the practice of breast cancer oncology
Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 749-759
2013
-
Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer
Oncologist, Vol. 18, Núm. 8, pp. 917-923
2011
-
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136
-
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132
2010
-
Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma
Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1
-
Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600